A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer

Boram Han,Joo Young Jung,Hyeong Su Kim,Ji Woong Cho,Kab Choong Kim,Hyun Lim,Ho Suk Kang,Hong Il Ha,Min Jeong Kim,Jung Hoon Kim,Dae Ro Choi,Geundoo Jang,Jung Han Kim,H. Song,Dae Young Zang

A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer

2016

Boram Han
Joo Young Jung
Hyeong Su Kim
Ji Woong Cho
Kab Choong Kim
Hyun Lim
Ho Suk Kang
Hong Il Ha
Min Jeong Kim
Jung Hoon Kim
Dae Ro Choi
Geundoo Jang
Jung Han Kim
H. Song
Dae Young Zang

Purposes To determine the maximum tolerated dose (MTD), recommended dose (RD), and activity of combined oxaliplatin, irinotecan, and S-1 chemotherapy for metastatic or recurrent gastrointestinal (GI) cancer.

Keywords:

Cancer
Maximum tolerated dose
Gastrointestinal cancer
Cancer research
Oncology
Pharmacology
Oxaliplatin
Internal medicine
Medicine
Chemotherapy
Irinotecan
in patient
dose finding

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations